Share

July 03, 2012; 79 (1) Articles

Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis

Michael Ruecker, Benjamin Matosevic, Peter Willeit, Matthias Kirchmayr, Alexandra Zangerle, Michael Knoflach, Johann Willeit, Stefan Kiechl
First published May 30, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31825dcdf0
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
532

Share

Article Information

vol. 79 no. 1 31-38
DOI: 
https://doi.org/10.1212/WNL.0b013e31825dcdf0
PubMed: 
22649217
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 23, 2011
  • Accepted November 17, 2011
  • First Published May 30, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. Michael Ruecker, MD,
    2. Benjamin Matosevic, MD,
    3. Peter Willeit, MD,
    4. Matthias Kirchmayr, MD,
    5. Alexandra Zangerle, MD,
    6. Michael Knoflach, MD,
    7. Johann Willeit, MD and
    8. Stefan Kiechl, MD
  1. Michael Ruecker, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Benjamin Matosevic, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Peter Willeit, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Matthias Kirchmayr, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Alexandra Zangerle, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Michael Knoflach, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Johann Willeit, MD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Stefan Kiechl, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Academic editor of PLOS One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Austrian Funding Agency FWG TRP 188-B12 Role of Iron in Atherosclerosis

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.R., B.M., P.W., M.K., A.Z., M.K., J.W., S.K.), Medical University Innsbruck, Innsbruck, Austria; and Department of Public Health and Primary Care (P.W.), University of Cambridge, Cambridge, UK.
  1. Correspondence & reprint requests to Dr. Kiechl: Stefan.Kiechl{at}i-med.ac.at

Article usage

Article usage: May 2012 to November 2023

AbstractFullPdfSource
May 2012169012Highwire
Jun 2012505033Highwire
Jul 2012196290165Highwire
Aug 20122642935Highwire
Sep 2012117822Highwire
Oct 2012122921Highwire
Nov 20127358Highwire
Dec 201273510Highwire
Jan 20137237Highwire
Feb 2013491014Highwire
Mar 20136076Highwire
Apr 20135134Highwire
May 20135643Highwire
Jun 20134996Highwire
Jul 20135731Highwire
Aug 20133433Highwire
Sep 20135610Highwire
Oct 20133623Highwire
Nov 20133912Highwire
Dec 20134657Highwire
Jan 20143432Highwire
Feb 20142355Highwire
Mar 20145211Highwire
Apr 20143532Highwire
May 20141513Highwire
Jun 20143100Highwire
Jul 20143800Highwire
Aug 20146501Highwire
Sep 20146533Highwire
Oct 20145501Highwire
Nov 20146733Highwire
Dec 20144801Highwire
Jan 20155701Highwire
Feb 20155600Highwire
Mar 20156222Highwire
Apr 20153700Highwire
May 20154200Highwire
Jun 20154000Highwire
Jul 20155034Highwire
Aug 20155301Highwire
Sep 20154400Highwire
Oct 20155553Highwire
Nov 20152600Highwire
Dec 20152800Highwire
Jan 20163421Highwire
Feb 20161434Highwire
Mar 20162012Highwire
Apr 20161921Highwire
May 20161900Highwire
Jun 2016801Highwire
Jul 20162500Highwire
Aug 20163300Highwire
Sep 20162400Highwire
Oct 20161300Highwire
Nov 2016910Highwire
Dec 20161220Highwire
Jan 20171600Highwire
Feb 20171400Highwire
Mar 20172201Highwire
Apr 20171922Highwire
May 20171400Highwire
Jun 20171400Highwire
Jul 20171523Highwire
Aug 2017901Highwire
Sep 20171300Highwire
Oct 20171522Highwire
Nov 20171301Highwire
Dec 20172101Highwire
Jan 20181432Highwire
Feb 20182110Highwire
Mar 20183302Highwire
Apr 20184902Highwire
May 20183402Highwire
Jun 20182500Highwire
Jul 20181410Highwire
Aug 20181311Highwire
Sep 20181216Highwire
Oct 20183216Highwire
Nov 20181012Highwire
Dec 20181514Highwire
Jan 20191003Highwire
Feb 20191302Highwire
Mar 2019811Highwire
Apr 20191014Highwire
May 20191002Highwire
Jun 20191803Highwire
Jul 2019501Highwire
Aug 20191045Highwire
Sep 20191001Highwire
Oct 20192201Highwire
Nov 20192126Highwire
Dec 20192301Highwire
Jan 20201204Highwire
Feb 20201406Highwire
Mar 2020503Highwire
Apr 2020600Highwire
May 20201100Highwire
Jun 20201001Highwire
Jul 2020300Highwire
Aug 20201000Highwire
Sep 2020911Highwire
Oct 2020801Highwire
Nov 20201632Highwire
Dec 20202202Highwire
Jan 20211900Highwire
Feb 20212710Highwire
Mar 20211000Highwire
Apr 20211500Highwire
May 20212100Highwire
Jun 20211500Highwire
Jul 20211801Highwire
Aug 20211600Highwire
Sep 20211202Highwire
Oct 20213743Highwire
Nov 20212604Highwire
Dec 20213901Highwire
Jan 20222302Highwire
Feb 20223502Highwire
Mar 20222704Highwire
Apr 20223800Highwire
May 20223311Highwire
Jun 20222300Highwire
Jul 20223112Highwire
Aug 20223801Highwire
Sep 20224006Highwire
Oct 20223212Highwire
Nov 20224041Highwire
Dec 20223414Highwire
Jan 20234400Highwire
Feb 20231301Highwire
Mar 20232301Highwire
Apr 20232700Highwire
May 20232801Highwire
Jun 20232000Highwire
Jul 20232000Highwire
Aug 20232110Highwire
Sep 20233100Highwire
Oct 20231721Highwire
Nov 20232300Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles